Lyell Immunopharma, Inc. — Director's Dealing 2021

Jun 17, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Lyell Immunopharma, Inc. (LYEL)
CIK: 0001806952
Period of Report: 2021-06-16

Reporting Person: Homans Elizabeth (Director, Chief Executive Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$0.10	2028-11-05	Common Stock (3469198)		Direct
Option (right to buy)	$0.10	2028-11-05	Common Stock (693840)		Direct
Option (right to buy)	$3.65	2030-01-15	Common Stock (230000)		Direct
Option (right to buy)	$5.81	2030-07-14	Common Stock (3352300)		Direct
Option (right to buy)	$6.24	2031-02-11	Common Stock (583532)		Direct

Footnotes

F1: 1/4 of the option shares vested on September 17, 2019, with the remaining option shares to vest in equal monthly installments over the following thirty-six months. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

F2: 1/4 of the option shares vested on November 6, 2019, with the remaining option shares to vest in equal monthly installments over the following thirty-six months. The option provides for an early-exercise provision and is exercisable as to unvested shares, subject to the Issuer's right of repurchase.

F3: The shares vest in equal monthly installments over the forty-eight months following February 1, 2020.

F4: The shares vest in equal monthly installments over the forty-eight months following August 1, 2020.

F5: The shares vest in equal monthly installments over the forty-eight months following February 12, 2021.